MCID: NRV006
MIFTS: 55

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15 17
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 72
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 72
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 44
Nervous System--Cancer 72
Nervous System Tumor 55
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 35 192 192.9
MeSH 44 D009380
NCIt 50 C35562
UMLS 72 C0027665 C0027766 C0153643 more

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to autonomic nervous system neoplasm and central nervous system cancer. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are ERK Signaling and Cell Cycle, Mitotic. The drugs Prednisone and Clavulanate have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and cellular

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 35.3 TP53 MYCN ENO2 CASP3
2 central nervous system cancer 34.9 TP53 SHH NF2 NF1 MYCN IDH1
3 peripheral nervous system neoplasm 32.7 TP53 NF2 NF1 MYCN ENO2 CASP3
4 ewing sarcoma 32.7 TP53 RB1 MYCN ENO2 CDKN2A CDK4
5 brain cancer 32.5 TP53 SHH RB1 NF2 NF1 MYCN
6 ependymoma 32.2 RB1 NF2 ENO2
7 spinal meningioma 31.6 NF2 NF1 ENO2
8 neurofibroma 31.4 NF2 NF1 CDKN2A
9 meningioma, familial 31.4 TP53 NF2 NF1 ENO2 CDKN2A
10 ewing's family of tumors 31.3 RB1 CDKN2B CDKN2A CDK4
11 plexiform schwannoma 31.3 NF2 NF1 ENO2
12 neurofibromatosis, type iv, of riccardi 31.3 NF2 NF1 CDKN2B-AS1
13 cellular schwannoma 31.2 TP53 NF2 NF1 CDKN2A
14 grade iii astrocytoma 31.2 TP53 CDKN2B CDKN2A CDK4
15 juvenile pilocytic astrocytoma 31.1 TP53 NF1 ENO2 CDKN2A
16 li-fraumeni syndrome 31.1 TP53 NF1 IDH1 CDKN2A
17 neurilemmoma 31.0 NF2 NF1 ENO2
18 pineal parenchymal tumor of intermediate differentiation 31.0 NF1 IDH1 ENO2
19 skin melanoma 31.0 TP53 CDKN2B CDKN2A CASP3
20 oligodendroglioma 31.0 TP53 IDH1 ENO2 CDKN2B CDKN2A
21 small cell carcinoma 30.9 TP53 ENO2 CDKN2A
22 malignant peripheral nerve sheath tumor 30.9 TP53 NF2 NF1 CDKN2A CDK4
23 papilloma 30.8 TP53 RB1 CDKN2B CDKN2A CCND1
24 leukemia, acute myeloid 30.8 TP53 IDH1 CDKN2B-AS1 CDKN2B CASP3
25 gastrointestinal stromal tumor 30.8 TP53 NF1 ENO2 CDKN2A CCND1
26 gliosarcoma 30.7 TP53 RB1 IDH1 ENO2 CDK4
27 lymphoma, non-hodgkin, familial 30.7 TP53 CDKN2B CCND1 CASP3
28 rhabdomyosarcoma 30.7 TP53 MYCN ENO2 CDK4
29 small cell cancer of the lung 30.7 TP53 RB1 MYCN ENO2 CDKN2A
30 adenocarcinoma 30.7 TP53 RB1 CDKN2A CDK4 CCND1
31 glioblastoma multiforme 30.6 TP53 RB1 IDH1 GLIPR1 CDKN2A CDK4
32 leiomyosarcoma 30.6 TP53 ENO2 CDK4
33 myelodysplastic syndrome 30.6 TP53 NF1 MIR34A IDH1 CDKN2B
34 melanoma 30.5 TP53 MIR34A CDKN2B-AS1 CDKN2A CDK4
35 spindle cell lipoma 30.5 RB1 CDK4
36 retinoblastoma 30.4 TP53 RBL1 RB1 MIR34A CDKN2A CDK4
37 pancreatic cancer 30.4 TP53 MIR34A CDKN2B-AS1 CDKN2A CDK4 CCND1
38 glioma 30.4 TP53 NF1 MIR34A IDH1 GLIPR1 CDKN2B-AS1
39 glioblastoma 30.3 TP53 RB1 NF1 MYCN MIR34A IDH1
40 breast cancer 30.2 TP53 RB1 NF1 MIR34A IDH1 GNRH1
41 esophageal cancer 30.2 TP53 RB1 MIR34A CDKN2B-AS1 CDKN2B CDKN2A
42 medulloblastoma 30.1 TP53 SHH MYCN MIR34A IDH1 ENO2
43 askin's tumor 29.8 MYCN ENO2
44 lung cancer 29.7 TP53 RB1 MYCN MIR34A ENO2 CDKN2B-AS1
45 inherited nervous system cancer-predisposing syndrome 12.3
46 olfactory neural tumor 12.3
47 mismatch repair cancer syndrome 11.6
48 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.6
49 glioma susceptibility 1 11.4
50 rare nervous system tumor 11.3

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK2 CDK4 ENO2 MYCN RBL1

MGI Mouse Phenotypes related to Nervous System Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
2 growth/size/body region MP:0005378 10.46 CASP3 CCND1 CDK2 CDK4 CDKN2A ENO2
3 homeostasis/metabolism MP:0005376 10.46 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
4 behavior/neurological MP:0005386 10.41 CASP3 CCND1 CDK4 CDKN2A ENO2 MYCN
5 endocrine/exocrine gland MP:0005379 10.4 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
6 immune system MP:0005387 10.39 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
7 mortality/aging MP:0010768 10.39 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
8 hematopoietic system MP:0005397 10.38 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
9 cardiovascular system MP:0005385 10.36 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN
10 digestive/alimentary MP:0005381 10.35 CASP3 CCND1 CDK4 CDKN2A GNRH1 MYCN
11 integument MP:0010771 10.35 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
12 craniofacial MP:0005382 10.31 CASP3 CCND1 ENO2 MYCN NF1 NF2
13 embryo MP:0005380 10.3 CDK2 CDK4 CDKN2A MYCN NF1 NF2
14 neoplasm MP:0002006 10.29 CCND1 CDK2 CDK4 CDKN2A CDKN2B GLIPR1
15 nervous system MP:0003631 10.27 CASP3 CCND1 CDK4 CDKN2A ENO2 GNRH1
16 liver/biliary system MP:0005370 10.26 CDK2 CDK4 CDKN2A GNRH1 MYCN NF1
17 muscle MP:0005369 10.19 CASP3 CDK2 CDK4 CDKN2A MYCN NF1
18 hearing/vestibular/ear MP:0005377 10.12 CASP3 NF1 NF2 RB1 RBL1 SHH
19 reproductive system MP:0005389 10.1 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
20 normal MP:0002873 10.06 CCND1 CDK4 GNRH1 MYCN NF1 RB1
21 renal/urinary system MP:0005367 10.06 CASP3 CDK4 CDKN2B GNRH1 MYCN NF1
22 no phenotypic analysis MP:0003012 10.03 CASP3 CDKN2A CDKN2B MYCN RB1 RBL1
23 respiratory system MP:0005388 9.93 CASP3 CCND1 CDKN2A ENO2 IDH1 MYCN
24 pigmentation MP:0001186 9.85 CASP3 CDK4 CDKN2A NF1 RB1 TP53
25 skeleton MP:0005390 9.73 CASP3 CCND1 CDKN2A GNRH1 IDH1 MYCN
26 vision/eye MP:0005391 9.4 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 441)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
3
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
4 Orange Approved Phase 3
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
8
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
11
Trioxsalen Approved Phase 3 3902-71-4 5585
12
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
13
Thioguanine Approved Phase 3 154-42-7 2723601
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
19
Etoposide Approved Phase 3 33419-42-0 36462
20
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
21
Lenograstim Approved, Investigational Phase 3 135968-09-1
22
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
23
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
24
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
25
leucovorin Approved Phase 3 58-05-9 143 6006
26
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
27
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
28
Cisatracurium Approved Phase 3 96946-41-7
29
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
32
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
33
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
36 Mitolactol Investigational Phase 3 10318-26-0
37
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
38 Antitubercular Agents Phase 3
39 Amoxicillin-Potassium Clavulanate Combination Phase 3
40 beta-Lactamase Inhibitors Phase 3
41 BB 1101 Phase 3
42 Analgesics Phase 3
43 Central Nervous System Depressants Phase 3
44 Peripheral Nervous System Agents Phase 3
45 Antiemetics Phase 3
46 Autonomic Agents Phase 3
47 Emetics Phase 3
48 Dihematoporphyrin Ether Phase 3
49 Hematoporphyrin Derivative Phase 3
50 Hematoporphyrins Phase 3

Interventional clinical trials:

(show top 50) (show all 594)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
4 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
10 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
11 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
12 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
13 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
14 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
15 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
16 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
17 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
18 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
19 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
20 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
21 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
22 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
23 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
24 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
25 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
26 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
27 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
28 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
29 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
30 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
31 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
32 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
33 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
34 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
35 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
36 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
37 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
38 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
39 Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation Active, not recruiting NCT00653068 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Leucovorin Calcium;Methotrexate;Thiotepa;Vincristine Sulfate
40 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
41 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
42 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
43 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
44 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
45 A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours Including CNS Tumours Unknown status NCT02303028 Phase 1, Phase 2 Topotecan and Pazopanib
46 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
47 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
48 Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
49 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
50 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

MalaCards organs/tissues related to Nervous System Cancer:

41
Brain, T Cells, Lung, Prostate, Testes, Bone, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

19
Nervous System

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show top 50) (show all 183)
# Title Authors PMID Year
1
Genetic epidemiology of colorectal cancer and associated cancers. 38
31424514 2019
2
The Association between Mortality-to-Incidence Ratios and Health Expenditures in Brain and Nervous System Cancers. 38
31370357 2019
3
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 38
31049790 2019
4
Glioma stages prediction based on machine learning algorithm combined with protein-protein interaction networks. 38
31150762 2019
5
Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. 38
30825593 2019
6
Retrospective Exposure Assessment for Semiconductor and Storage Device Manufacturing Facilities. 38
30946698 2019
7
Mortality among autoworkers manufacturing electronics in Huntsville, Alabama. 38
30569473 2019
8
Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. 38
31013819 2019
9
Radiological imaging and orthodontic treatment in the case of growing patients after oncological treatment: Case reports. 38
31099502 2019
10
Fluorodeoxyglucose Detected Changes in Brain Metabolism After Chemotherapy in Pediatric Non-Hodgkin Lymphoma. 38
30630683 2019
11
Familial Associations of Colon and Rectal Cancers With Other Cancers. 38
30640834 2019
12
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. 38
30350913 2019
13
miR-26b Mimic Inhibits Glioma Proliferation In Vitro and In Vivo Suppressing COX-2 Expression. 38
28800785 2019
14
Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study. 38
30694203 2019
15
Functional Polymorphisms in BARD1 Association with Neuroblastoma in a regional Han Chinese Population. 38
31258718 2019
16
Risk of Radiation-Induced Cancer From Computed Tomography Angiography Use in Imaging Surveillance for Unruptured Cerebral Aneurysms. 38
30580703 2018
17
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 38
30585513 2018
18
Cancer and dementia: Two sides of the same coin? 38
30112764 2018
19
Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients. 38
30264947 2018
20
Exosomes impact survival to radiation exposure in cell line models of nervous system cancer. 38
30546829 2018
21
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 38
30395335 2018
22
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells. 38
30199037 2018
23
Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. 38
29696364 2018
24
Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. 38
29461625 2018
25
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. 38
29511029 2018
26
Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. 38
29427203 2018
27
Integrated analysis of microarray data to identify the genes critical for the rupture of intracranial aneurysm. 38
29552131 2018
28
Outcomes of Organ Transplantation from Donors with a Cancer History. 38
29455213 2018
29
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 38
30140655 2018
30
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. 38
29374660 2018
31
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. 38
28426850 2017
32
Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. 38
28770444 2017
33
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. 38
30034079 2017
34
Improving Functional Mobility in Children and Adolescents Undergoing Treatment for Non-Central Nervous System Cancers: A Systematic Review. 38
28942910 2017
35
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. 38
28497710 2017
36
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. 38
28503718 2017
37
Biomarkers and Immunotherapeutic Targets in Glioblastoma. 38
28300714 2017
38
Integrated analysis of genome-wide DNA methylation and gene expression data provide a regulatory network in intrauterine growth restriction. 38
28465243 2017
39
Estimating the Proportion of Childhood Cancer Cases and Costs Attributable to the Environment in California. 38
28323471 2017
40
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. 38
29270434 2017
41
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. 38
27151596 2016
42
The Incidence of Malignant Tumors in Environmentally Disadvantaged Regions of Kazakhstan 38
28125862 2016
43
Expression and prognostic significance of CCL11/CCR3 in glioblastoma. 38
27119233 2016
44
A novel TP53 variant (rs78378222 A > C) in the polyadenylation signal is associated with increased cancer susceptibility: evidence from a meta-analysis. 38
27147571 2016
45
Low Grade Gliomas in Children. 38
26286938 2016
46
Investigation of cancer mortality inequalities between rural and urban areas in South Korea. 38
26123204 2016
47
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. 38
26908235 2016
48
Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. 38
26806350 2016
49
Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. 38
26344551 2015
50
Paediatric brain tumours: A review of radiotherapy, state of the art and challenges for the future regarding protontherapy and carbontherapy. 38
26548600 2015

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 TP53 RBL1 RB1 NF1 GNRH1 CDKN2B
2
Show member pathways
13.45 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
3
Show member pathways
13.14 TP53 RB1 CDKN2B CDKN2A CDK4 CDK2
4
Show member pathways
13.04 TP53 RBL1 RB1 CDK4 CDK2 CCND1
5
Show member pathways
13.01 TP53 RB1 CDKN2A CDK4 CDK2 CCND1
6
Show member pathways
12.93 TP53 RB1 CDKN2A CDK4 CDK2 CCND1
7 12.85 TP53 SHH RB1 CDKN2B CDKN2A CDK4
8
Show member pathways
12.79 TP53 SHH RB1 CDKN2B CDKN2A CDK4
9
Show member pathways
12.76 TP53 RBL1 RB1 CDK4 CDK2 CCND1
10
Show member pathways
12.73 TP53 RB1 NF1 CDKN2B CDKN2A CDK4
11 12.59 TP53 RB1 CDKN2A CDK4 CDK2 CCND1
12
Show member pathways
12.58 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
13 12.57 TP53 MIR34A CDKN2A CCND1 CASP3
14 12.5 TP53 RBL1 RB1 CDK4 CDK2 CCND1
15 12.43 TP53 RB1 CDKN2B CDKN2A CDK4 CCND1
16
Show member pathways
12.41 TP53 RB1 CDKN2A CDK4 CDK2 CCND1
17 12.37 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
18 12.32 TP53 SHH CCND1 CASP3
19
Show member pathways
12.32 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
20
Show member pathways
12.31 TP53 RB1 CDK4 CDK2 CCND1 CASP3
21
Show member pathways
12.29 RB1 CDKN2B CDKN2A CDK4 CDK2 CCND1
22
Show member pathways
12.28 TP53 RB1 CDK4 CDK2 CCND1 CASP3
23
Show member pathways
12.2 RB1 CDK4 CDK2 CCND1
24 12.2 TP53 CDK4 CDK2 CCND1 CASP3
25 12.16 TP53 RB1 NF1 CDK4 CDK2 CCND1
26 12.11 TP53 RBL1 CDKN2B CCND1
27
Show member pathways
12.09 NF1 CDK4 CDK2 CCND1
28 12.07 TP53 RB1 CDKN2A CDK2
29 12.07 TP53 RB1 CDK4 CDK2 CCND1 CASP3
30
Show member pathways
12.05 TP53 RBL1 RB1 CDK4 CDK2 CCND1
31 11.96 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
32 11.92 TP53 RB1 CDK4 CDK2 CCND1
33 11.91 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
34 11.9 CDK4 CCND1 CASP3
35 11.85 RBL1 CDKN2B CDK4 CDK2
36 11.81 TP53 RB1 CDKN2A CDK4 CCND1
37 11.76 TP53 RB1 CDKN2B CDK4 CDK2 CCND1
38
Show member pathways
11.75 TP53 CDKN2A CDK2
39 11.75 TP53 CDKN2A CASP3
40 11.75 RBL1 RB1 CDK2
41 11.73 TP53 RB1 CDKN2A CDK2
42 11.72 RB1 CDK4 CDK2
43 11.66 RBL1 CDKN2B CCND1
44 11.64 TP53 RB1 CDKN2A CCND1
45 11.62 NF1 CDK4 CCND1
46 11.61 TP53 CCND1 CASP3
47 11.58 TP53 CCND1 CASP3
48 11.57 TP53 CDK4 CDK2 CCND1
49 11.54 RB1 NF1 CDK2
50 11.47 RB1 CDK4 CDK2 CCND1

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.46 RBL1 RB1 CDK4 CDK2
2 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CDK4 CDK2 CCND1
3 chromatin GO:0000785 8.92 RBL1 RB1 MYCN CDK4

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.98 TP53 NF1 CDKN2A CDK4 CASP3
2 regulation of gene expression GO:0010468 9.93 SHH NF1 GNRH1 CDK4
3 positive regulation of gene expression GO:0010628 9.93 TP53 SHH MYCN MIR34A CDKN2B-AS1 CDKN2A
4 cell cycle GO:0007049 9.92 TP53 RBL1 RB1 CDKN2B CDKN2A CDK4
5 regulation of cell proliferation GO:0042127 9.89 SHH NF2 NF1 CDK4
6 negative regulation of gene expression GO:0010629 9.89 SHH RBL1 RB1 MYCN CDKN2B-AS1
7 cell cycle arrest GO:0007050 9.86 TP53 RB1 CDKN2B CDKN2A
8 response to organic cyclic compound GO:0014070 9.85 IDH1 GNRH1 CCND1 CASP3
9 negative regulation of cell migration GO:0030336 9.84 SHH NF2 NF1 MIR34A
10 response to organic substance GO:0010033 9.82 CDK4 CCND1 CASP3
11 response to glucocorticoid GO:0051384 9.79 CCND1 CASP3 BCHE
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 RBL1 RB1 CDKN2B
13 negative regulation of protein kinase activity GO:0006469 9.73 RB1 NF2 NF1 CDKN2A
14 response to steroid hormone GO:0048545 9.69 IDH1 GNRH1 CCND1
15 ectoderm development GO:0007398 9.65 SHH NF2
16 negative regulation of cell-matrix adhesion GO:0001953 9.65 NF2 NF1 CDKN2A
17 G1/S transition of mitotic cell cycle GO:0000082 9.65 RB1 CDKN2A CDK4 CDK2 CCND1
18 replicative senescence GO:0090399 9.64 TP53 CDKN2A
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 MYCN
20 regulation of protein localization to nucleus GO:1900180 9.61 SHH NF2
21 striated muscle cell differentiation GO:0051146 9.58 SHH RB1 CASP3
22 regulation of lipid kinase activity GO:0043550 9.57 RBL1 RB1
23 Ras protein signal transduction GO:0007265 9.55 TP53 RB1 NF1 CDKN2A CDK2
24 mitotic G1 DNA damage checkpoint GO:0031571 9.54 TP53 CDK2 CCND1
25 glial cell apoptotic process GO:0034349 9.52 RB1 CASP3
26 regulation of cell cycle GO:0051726 9.43 RBL1 RB1 NF2 CDK4 CDK2 CCND1
27 negative regulation of cell proliferation GO:0008285 9.23 TP53 RB1 NF2 NF1 GNRH1 CDKN2B
28 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 TP53 SHH RBL1 RB1 MYCN CDKN2B
29 negative regulation of transcription by RNA polymerase II GO:0000122 10.11 TP53 SHH RBL1 RB1 CDK2 CCND1
30 positive regulation of transcription, DNA-templated GO:0045893 10.05 TP53 SHH RB1 MYCN CDKN2A CDK2

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.65 TP53 RBL1 RB1 CDKN2A CCND1
2 disordered domain specific binding GO:0097718 9.33 TP53 RB1 CDKN2A
3 RNA polymerase II regulatory region DNA binding GO:0001012 9.32 RBL1 RB1
4 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.96 CDK4 CDK2
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN2B CDKN2A CASP3

Sources for Nervous System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....